Table 3.
PSA recurrencea by treatment and by tumour epithelial volume based on Kaplan-Meier method with log-rank test
| Treatment (p = 0.28) | Tumour epithelial volume (p = 0.001) | Pathological stage (p = 0.0002) | ||||
|---|---|---|---|---|---|---|
| AAP + LHRHa | LHRHa | ≤0.3 cc | >0.3 cc | ypT2N0 | >pT2N0 | |
| 3-yrs RFS(%) | 75 | 71 | 89 | 61 | 89 | 60 |
| Recurrence | 19 | 10 | 8 | 21 | 8 | 21 |
| No recurrence | 24 | 7 | 20 | 11 | 18 | 13 |
| Loss to follow-up | 1 | 2 | 1 | 2 | 1 | 2 |
| Death from other primary reason | 0 | 2 | 0 | 2 | 2 | 0 |
AAP = abiraterone acetate plus prednisone; LHRHa= luteinising hormone-releasing hormone agonist; PSA = prostate-specific antigen; RFS = relapse-free survival.
a
Defined as a ≥0.1 ng/ml rise in PSA levels.
We explored biomarkers by association with treatment arm and residual volume, and then focused within the abiraterone treatment arm.